SPL Stock Overview
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.13 |
52 Week High | AU$0.53 |
52 Week Low | AU$0.12 |
Beta | 0.82 |
1 Month Change | -3.85% |
3 Month Change | -26.47% |
1 Year Change | -73.12% |
3 Year Change | -93.90% |
5 Year Change | -88.69% |
Change since IPO | -84.38% |
Recent News & Updates
Recent updates
Does Starpharma Holdings (ASX:SPL) Have A Healthy Balance Sheet?
Dec 18We Think Some Shareholders May Hesitate To Increase Starpharma Holdings Limited's (ASX:SPL) CEO Compensation
Nov 22Here's Why Starpharma Holdings (ASX:SPL) Can Manage Its Debt Despite Losing Money
Mar 21We're Hopeful That Starpharma Holdings (ASX:SPL) Will Use Its Cash Wisely
Jan 26We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
Jun 21Starpharma Holdings Limited (ASX:SPL): Is Breakeven Near?
May 16Here's Why We're Not At All Concerned With Starpharma Holdings' (ASX:SPL) Cash Burn Situation
Mar 02Is There An Opportunity With Starpharma Holdings Limited's (ASX:SPL) 27% Undervaluation?
Feb 10Starpharma Holdings Limited (ASX:SPL) Is Expected To Breakeven In The Near Future
Jan 20Did You Miss Starpharma Holdings' (ASX:SPL) Impressive 105% Share Price Gain?
Dec 28How Does Starpharma Holdings' (ASX:SPL) CEO Salary Compare to Peers?
Dec 07Shareholder Returns
SPL | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | 0% | 1.1% | 1.5% |
1Y | -73.1% | 44.7% | 11.6% |
Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned 44.7% over the past year.
Return vs Market: SPL underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
SPL volatility | |
---|---|
SPL Average Weekly Movement | 10.1% |
Pharmaceuticals Industry Average Movement | 10.6% |
Market Average Movement | 8.7% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: SPL's share price has been volatile over the past 3 months.
Volatility Over Time: SPL's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 45 | Cheryl Maley | https://starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.
Starpharma Holdings Limited Fundamentals Summary
SPL fundamental statistics | |
---|---|
Market cap | AU$51.51m |
Earnings (TTM) | -AU$8.39m |
Revenue (TTM) | AU$10.52m |
4.9x
P/S Ratio-6.1x
P/E RatioIs SPL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPL income statement (TTM) | |
---|---|
Revenue | AU$10.52m |
Cost of Revenue | AU$11.68m |
Gross Profit | -AU$1.16m |
Other Expenses | AU$7.24m |
Earnings | -AU$8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.02 |
Gross Margin | -11.02% |
Net Profit Margin | -79.79% |
Debt/Equity Ratio | 0% |
How did SPL perform over the long term?
See historical performance and comparison